Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-05-05 Sale |
2021-05-06 4:15 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
1,000 | $199.67 | $199,670 | 77,390 (Direct) |
View |
| 2021-05-04 Sale |
2021-05-05 4:09 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
1,043 | $200.86 | $209,493 | 102,562 (Direct) |
View |
| 2021-04-13 Sale |
2021-04-15 6:29 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Executive Chairman |
95,000 | $199.55 | $18,957,452 | 555,393 (Direct) |
View |
| 2021-04-13 Sale |
2021-04-15 6:01 pm |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
97,973 | $196.34 | $19,236,323 | 8,184 (Direct) |
View |
| 2021-04-13 Sale |
2021-04-15 6:00 pm |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
6,000 | $198.84 | $1,193,035 | 78,390 (Direct) |
View |
| 2021-04-13 Sale |
2021-04-15 5:59 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
5,958 | $200 | $1,191,600 | 67,565 (Direct) |
View |
| 2021-03-23 Sale(A) |
2021-04-09 4:25 pm |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
2,835 | $140 | $396,900 | 33,471 (Direct) |
View |
| 2021-04-01 Sale |
2021-04-02 4:14 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Executive Chairman |
7,928 | $134.12 | $1,063,303 | 650,393 (Direct) |
View |
| 2021-03-23 Sale |
2021-03-25 4:40 pm |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
3,892 | $140 | $544,880 | 40,198 (Direct) |
View |
| 2021-03-05 Sale |
2021-03-09 4:17 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
4,550 | $131.53 | $598,462 | 107,423 (Direct) |
View |
| 2021-03-05 Sale |
2021-03-09 4:16 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
2,918 | $131.53 | $383,805 | 33,259 (Direct) |
View |
| 2021-03-03 Sale |
2021-03-05 5:44 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
3,475 | $150.78 | $523,961 | 59,055 (Direct) |
View |
| 2021-02-22 Sale |
2021-02-24 4:16 pm |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
6,500 | $175.5 | $1,140,750 | 27,597 (Direct) |
View |
| 2021-01-15 Sale |
2021-01-19 5:00 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
63,814 | $172.48 | $11,006,647 | 59,660 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2021-05-05 Exercise |
2021-05-06 4:15 pm |
N/A 2028-05-30 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
1,000 | $0 | 77,390 (Direct) |
View |
| 2021-05-05 Exercise |
2021-05-06 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
1,000 | $31.45 | 77,390 (Direct) |
View |
| 2021-05-03 Exercise |
2021-05-05 4:09 pm |
2021-05-01 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
2,333 | $0 | 102,562 (Direct) |
View |
| 2021-05-03 Exercise |
2021-05-05 4:09 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
2,333 | $204.1 | 102,562 (Direct) |
View |
| 2021-04-13 Exercise |
2021-04-15 6:00 pm |
N/A 2028-05-31 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
6,000 | $0 | 78,390 (Direct) |
View |
| 2021-04-13 Exercise |
2021-04-15 6:00 pm |
N/A N/A |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
6,000 | $31.45 | 78,390 (Direct) |
View |
| 2021-04-13 Exercise |
2021-04-15 5:59 pm |
N/A 2029-05-07 |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
5,958 | $0 | 67,565 (Direct) |
View |
| 2021-04-13 Exercise |
2021-04-15 5:59 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
651 | $83.3 | 67,565 (Direct) |
View |
| 2021-04-13 Exercise |
2021-04-15 5:59 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
1,833 | $47.56 | 67,565 (Direct) |
View |
| 2021-04-13 Exercise |
2021-04-15 5:59 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
3,474 | $69.37 | 67,565 (Direct) |
View |
| 2021-03-31 Exercise |
2021-04-02 4:14 pm |
2019-03-31 N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Executive Chairman |
9,259 | $0 | 650,393 (Direct) |
View |
| 2021-03-31 Exercise |
2021-04-02 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Executive Chairman |
9,259 | $125.25 | 650,393 (Direct) |
View |
| 2021-03-23 Exercise |
2021-03-25 4:40 pm |
N/A 2029-03-21 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
3,892 | $0 | 40,198 (Direct) |
View |
| 2021-03-23 Exercise |
2021-03-25 4:40 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
3,892 | $47.04 | 40,198 (Direct) |
View |
| 2021-03-05 Exercise |
2021-03-09 4:17 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
13,987 | $0 | 107,423 (Direct) |
View |
| 2021-03-05 Exercise |
2021-03-09 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
13,987 | $7.15 | 107,423 (Direct) |
View |
| 2021-03-04 Gift |
2021-03-08 4:23 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
910 | $0 | 36,658 (Direct) |
View |
| 2021-03-03 Exercise |
2021-03-05 5:44 pm |
N/A 2030-03-02 |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
3,475 | $0 | 59,055 (Direct) |
View |
| 2021-03-03 Exercise |
2021-03-05 5:44 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
3,475 | $69.37 | 59,055 (Direct) |
View |
| 2021-03-02 Option Award |
2021-03-04 5:56 pm |
N/A N/A |
NovoCure Ltd | NVCR | Madden Martin J. Director |
111 | $0 | 15,224 (Indirect) |
View |
| 2021-03-02 Option Award |
2021-03-04 5:55 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
24,712 | $0 | 107,380 (Direct) |
View |
| 2021-03-02 Option Award |
2021-03-04 5:54 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
24,712 | $0 | 52,309 (Direct) |
View |
| 2021-03-02 Option Award |
2021-03-04 5:53 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
24,712 | $0 | 54,068 (Direct) |
View |
| 2021-03-02 Option Award |
2021-03-04 5:52 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
30,890 | $0 | 58,139 (Direct) |
View |
| 2021-03-02 Option Award |
2021-03-04 5:50 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
35,523 | $0 | 183,546 (Direct) |
View |
| 2021-03-02 Option Award |
2021-03-04 5:48 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
7,929 | $0 | 7,929 (Direct) |
View |
| 2021-03-02 Option Award |
2021-03-04 5:46 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
30,890 | $0 | 122,822 (Direct) |
View |
| 2021-03-02 Option Award |
2021-03-04 5:44 pm |
N/A 2031-03-01 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
29,346 | $0 | 92,206 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:18 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,086 | $0 | 92,844 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,086 | $149.1 | 92,844 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:17 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
9,259 | $0 | 206,944 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
9,259 | $149.1 | 206,944 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:15 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
5,555 | $0 | 65,215 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:15 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
5,555 | $149.1 | 65,215 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:14 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,465 | $0 | 27,677 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,465 | $149.1 | 27,677 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:12 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
1,465 | $0 | 83,098 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:12 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
1,465 | $149.1 | 83,098 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:11 pm |
2021-02-27 N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
7,715 | $0 | 150,415 (Direct) |
View |
| 2021-02-27 Exercise |
2021-03-02 4:11 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
7,715 | $149.1 | 150,415 (Direct) |
View |
| 2021-02-22 Exercise |
2021-02-24 4:16 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
6,500 | $0 | 27,597 (Direct) |
View |
| 2021-02-22 Exercise |
2021-02-24 4:16 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
6,500 | $7.15 | 27,597 (Direct) |
View |
Ownership |
2021-02-12 7:11 pm |
N/A N/A |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
0 | $0 | 75 (Direct) |
View |
| 2021-01-15 Exercise |
2021-01-19 5:00 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
36,396 | $0 | 59,660 (Direct) |
View |
| 2021-01-15 Exercise |
2021-01-19 5:00 pm |
N/A N/A |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
36,396 | $14.37 | 59,660 (Direct) |
View |